Global Post-Myocardial Infarction Market: Overview The most common term used to refer to myocardial infarction is heart-attack. In this report, TMR Research (TMR) delves into studying the factors causing the demand for post-myocardial infarction treatment. For the purpose of the study, TMR thus segments the global post-myocardial infarction market based on various parameters and then identifies opportunities prevalent across each of these segments. Continue reading →

Sophia Antipolis, Octobe 15, 2020: One in five high-risk patients undergoing major non-cardiac surgery will develop one or more heart complications within a year, according to research published today inEuropean Heart Journal Acute Cardiovascular Care, a journal of the European Society of Cardiology (ESC).1 Our study reveals a greater likelihood of having heart problems or dying after non-cardiac surgery than has been recognised to date, said study author Dr. Christian Puelacher of the University of Basel, Switzerland. Continue reading →

KANAGAWA, Japan (PRWEB) October 15, 2020 The non-clinical studies conducted by Metcela revealed at least two clear subpopulations of fibroblasts found in the human fetal heart: VCAM1-positive cardiac fibroblasts (VCFs) and VCAM1-negative cardiac fibroblasts (VNCFs). When examined with bioinformatics analyses, VCFs expressed numerous genes related to lymphatic vessel formation Continue reading →

For immediate release: October 12, 2020 Boston, MA The hospitalization rate for acute cardiovascular disease (CVD) events in a large southern California health system was 1.62 times higher in the two days immediately after the 2016 presidential election when compared with the same two days in the week prior to the 2016 election, according to new research from Harvard T.H. Chan School of Public Health and Kaiser Permanente. The results were similar across sex, age, and race and ethnicity groups, and the findings suggest that sociopolitical stress may trigger CVD events Continue reading →

1. In trauma patients at risk for hemorrhage, pre-hospital administration of tranexamic acid did not significantly improve 30-day mortality compared to a placebo Continue reading →

Oct. 14, 2020 16:00 UTC PROSPECT ABSORB, a randomized substudy, showed treatment of high risk plaques with BVS is safe and associated with favorable long-term clinical outcomes compared to GDMT alone BEDFORD, Mass.--(BUSINESS WIRE)--InfraReDx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of near-infrared spectroscopy (NIRS) imaging plus intravascular ultrasound (IVUS) to identify coronary plaques responsible for future coronary events. Continue reading →